The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Estimated clinical efficacy and radiographic response characteristics of PD1 inhibition in newly diagnosed and recurrent glioblastoma in clinical practice: A report from the iRANO Working Group.
 
Benjamin M. Ellingson
Consulting or Advisory Role - Agios; Bristol-Myers Squibb; Imaging Endpoints; Medicenna; MedQIA; Nativis; Northwest Biotherapeutics; Novogen; Omniox; Roche/Genentech; Siemens; Tocagen
Research Funding - Agios; Roche/Genentech; Siemens
Travel, Accommodations, Expenses - Siemens
 
Raymond Yi-kun Huang
Consulting or Advisory Role - Agios
Research Funding - Agios
 
Javier Villanueva-Meyer
No Relationships to Disclose
 
Mary Jane Lim-Fat
No Relationships to Disclose
 
Elizabeth George
No Relationships to Disclose
 
Bryan Iorgulescu
No Relationships to Disclose
 
Geoffrey Young
No Relationships to Disclose
 
Catalina Raymond
No Relationships to Disclose
 
Talia Oughourlian
No Relationships to Disclose
 
Jacob Schlossman
No Relationships to Disclose
 
Tyler Gleason
No Relationships to Disclose
 
Nancy Ann Oberheim Bush
No Relationships to Disclose
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; deciphera; Deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Alexion Pharmaceuticals; Amgen; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Celgene; cortice; Deciphera; DelMar Pharmaceuticals; Genocea Biosciences; GW Pharmaceuticals; Human Longevity, Inc; Insys Therapeutics; Karyopharm Therapeutics; KIYATEC; Lilly; Merck; NewGen Therapeutics; Notable Labs; Novartis; Novocure; Novogen; Oxigene; Pascal Biosciences; Pfizer; Puma Biotechnology; QED Therapeutics; Roche/Genentech; Sunovion; Tocagen; VBI Vaccines; VBL Therapeutics; wellcome trust
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Global Coalition for Adaptive Research
 
Susan Marina Chang
Research Funding - Agios (Inst); Novartis (Inst)
 
David A. Reardon
Honoraria - Advantagene; Agenus; Bayer; Bristol-Myers Squibb; DelMar Pharmaceuticals; EMD Serono; Imvax; Merck; Merck KGaA; Novartis; Novocure; Oncorus; Regeneron; Taiho Pharmaceutical
Consulting or Advisory Role - Advantagene; Agenus; Bayer; Bristol-Myers Squibb; Delmar Pharmaceuticals; EMD Serono; Imvax; Merck; Merck KGaA; Novartis; Novocure; Oncorus; Regeneron; Taiho Pharmaceutical
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Incyte (Inst); Omniox
 
Michael Weller
Honoraria - Abbvie; Merck Serono; MSD
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Karyopharm Therapeutics; Merck Serono; Orbus Therapeutics; Tocagen
Research Funding - Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novocure (Inst); OGD2 Pharma (Inst); Piqur (Inst); Roche (Inst); Tragara (Inst)
 
Hideho Okada
Consulting or Advisory Role - Amal Therapeutics; BrightPath Biotheraputics; Eureka Therapeutics; Refuge Biotech
Research Funding - Agios; Ono Pharmaceutical
Patents, Royalties, Other Intellectual Property - EGFRvIII-CAR - an exclusive licensing agreement has been executed with Novartis Pharma; IL-13Ra2 (345-353:1A9V) exclusive licensing agreement has been executed with Stemline, Inc.; Inventor of US utility patent application (Case #: SF2015-163) has been filed for H3.3 CTL peptides and uses thereof.; Inventor of US utility patent application (Case #: SF2015-163) has been filed for H3.3 CTL peptides and uses thereof.; Rheo-IL-12 exclusive licensing agreement has been executed with Intrexon Corporation; Three US provisional patients have been published (PCT/US2019/025846, PCT/US2019/025829, PCT/US2019/025860) for the use of synNotch circuits for treatment of solid cancers, including glioblastoma